HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a 'Buy' rating on Cara Therapeutics (NASDAQ:CARA) but has lowered the price target from $15 to $7.
October 19, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics' price target has been lowered from $15 to $7 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Cara Therapeutics by HC Wainwright & Co. indicates a potential decrease in the stock's value in the short term. However, the maintenance of the 'Buy' rating suggests that the analyst still sees potential in the stock, which could mitigate the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100